Previous 10 | Next 10 |
J.Jill (NYSE: JILL ) -51% on Q1 earnings . More news on: J.Jill, Inc., Aptose Biosciences Inc., Eltek Ltd., Stocks on the move, Read more ...
Zafgen (NASDAQ: ZFGN ) has received minutes from its Type A meeting with FDA regarding the clinical hold for ZGN-1061. More news on: Zafgen, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Received FDA Type A meeting minutes related to previously announced clinical hold FDA acknowledged newly developed in vitro assays of human plasma coagulation and tissue factor expression qualitatively differentiate ZGN-1061 Company is working with FDA to translate in vitro da...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 104 weeks of public selections as part of this ongoing live forward-testing. In...
Rhythm Pharmaceuticals ( RYTM ) is approaching a critical period. In Q3'19 the company is expected to report data from two phase 3 trials of its drug setmelanotide which are the major focus of this article. Setmelanotide in POMC deficiency obesity Setmelanotide is an agonist of the melanoc...
Zafgen (NASDAQ: ZFGN ): Q1 GAAP EPS of -$0.35 beats by $0.07 . More news on: Zafgen, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Recently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061 Company is currently in the formal regulatory process related to the clinical hold for ZGN-1061; Update still anticipated...
BOSTON, May 02, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that it will...
BOSTON, April 04, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN) (the “Company”) a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, to...
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Zafgen, Inc. (“Zafgen” or the “Company”) (NASDAQ: ZFGN ) investors concerning the Company and its officers’ possible violations of federal securities laws. ...
News, Short Squeeze, Breakout and More Instantly...
Zafgen Company Name:
ZFGN Stock Symbol:
NASDAQ Market:
- Shares of combined company to commence trading on Nasdaq Global Market under the symbol “LRMR” on May 29, 2020 - Company signed $80 million in private placement financing with biotechnology focused institutional investors - New Board Chair, Chief Medical Officer and Chi...
These Penny Stocks Moved Big But Can They Continue Higher Before Next Year? Over the course of the year, plenty of penny stocks have generated significant gains for investors. Even as the year comes to a close, there are some penny stocks that are gaining momentum. It is often said that inve...
Creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseases Chondrial Therapeutics’ lead asset, CTI-1601, currently being evaluated in Phase 1 clinical trial for Friedreich’s ataxia Companies to host confere...